James Delgadillo
Internal Medicine · Eau Claire, WINPI 1619258019
Payments from drug & device makers
Across 135 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$542
- AbbVie$398
- Lilly USA, LLC$318
- Johnson & Johnson$143
- Phathom Pharmaceuticals, Inc.$100
- Novo Nordisk$98
- plus $688 from 19 others
What the payments were for
- Food & beverage$2,288100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $542 |
| AbbVie(2 entities) | 30 | $398 |
| Lilly USA, LLC | 19 | $318 |
| Johnson & Johnson | 9 | $143 |
| Phathom Pharmaceuticals, Inc. | 6 | $100 |
| Novo Nordisk | 7 | $98 |
| GSK | 5 | $71 |
| Amarin Pharma, Inc. | 4 | $63 |
| Esperion Therapeutics, Inc. | 4 | $61 |
| Supernus Pharmaceuticals, Inc. | 4 | $55 |
| Amgen | 3 | $52 |
| Daiichi Sankyo Inc. | 3 | $43 |
| Pfizer | 3 | $42 |
| Gilead | 3 | $41 |
| Abbott | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Astellas Pharma US Inc | 1 | $25 |
| Boehringer Ingelheim | 2 | $25 |
| Mylan Specialty L.p. | 1 | $21 |
| Medtronic | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,288 in reported general payments places this provider in the 90th percentile of 1,411 internal medicine providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 516 | $938,693 |
| EliquisApixaban | 297 | $474,078 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 250 | $429,573 |
| FarxigaDapagliflozin Propanediol | 248 | $397,106 |
| JardianceEmpagliflozin | 208 | $354,165 |
| MounjaroTirzepatide | 97 | $172,011 |
| XareltoRivaroxaban | 123 | $167,787 |
| Tresiba Flextouch U-100Insulin Degludec | 100 | $121,278 |
| JanuviaSitagliptin Phosphate | 77 | $120,506 |
| EntrestoSacubitril/Valsartan | 81 | $106,229 |
| Xigduo XrDapaglifloz Propaned/Metformin | 55 | $88,677 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $83,695 |
| LinzessLinaclotide | 36 | $54,317 |
| Repatha SureclickEvolocumab | 36 | $49,107 |
| Novolog FlexpenInsulin Aspart | 70 | $34,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $98 | $938,693516 claims |
| PfizerEliquis | $42 | $474,078297 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $542 | $448,932302 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $71 | $445,742266 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta | $25 | $407,857248 claims |
| Lilly USA, LLCMounjaro | $318 | $172,01197 claims |
| Johnson & JohnsonXarelto | $143 | $167,787123 claims |
| AbbVieLinzess, Creon, Vraylar, Restasis | $398 | $117,41375 claims |
| NovartisEntresto | $14 | $106,22981 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $21,54823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,411 internal medicine providers in Wisconsin.
Other internal medicine in Eau Claire
- Michael SmithEau Claire$8K
- Joseph KittahEau Claire$8K
- Nicholas SiebersMadison$47.3M
- Irene MirkinMiddleton$42.9M
- John BlanchardMadison$17.2M
- Carlos SanabriaWest Bend$12.9M
- Andrew KimWauwatosa$2.3M
- Jeremiah DeptaMilwaukee$2.2M
- Gilbert JenouriMilwaukee$2.2M
- Stephen FlachMadison$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.